Skip to main content
. 2021 Jul 28;11(7):e045797. doi: 10.1136/bmjopen-2020-045797

Table 3.

HRs for type 2 diabetes in prostate cancer by use of ADT

HR 95% CI aHR* 95% CI
ADT-free cohort ref. ref.
ADT users 1.49 1.34 to 1.66 1.47 1.32 to 1.64
GnRH agonists users 1.53 1.38 to 1.71 1.51 1.35 to 1.69
Antiandrogen users 1.02 0.75 to 1.40 1.02 0.74 to 1.39

*Adjusted for age and stage.

ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone.